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a b s t r a c tThe mammalian target of rapamycin (mTOR) inhibitor everolimus is a narrow therapeutic index drug for which
optimal exposure levels are essential. The consistent pharmacokinetic proﬁle of everolimus allows trough concen-
tration (C0)measurement to be an appropriate and reliable index for therapeutic drugmonitoring (TDM). Exposure-
response analyses of data from early ﬁxed-dose trials demonstrated that rates of biopsy-proven acute rejection
(BPAR) are signiﬁcantly higher if everolimus C0 declines below 3 ng/mL, an observation conﬁrmed in subsequent
concentration-controlled trials. Evidence for the most favorable upper limit is less clear but with reduced-
exposure calcineurin inhibitor (CNI) therapy, an upper limit of 8 ng/mL appears to balance efﬁcacy and safety
outcomes. The recommended C0 range is 3–8 ng/mL in kidney, liver and heart transplantation patients, based on
LC–MS/MS monitoring in whole blood. Randomized clinical trials based on this target range have demon-
strated rates of BPAR comparable to a regimen of mycophenolic acid with standard-exposure CNI. Everoli-
mus exhibits moderate intrapatient pharmacokinetic variability, and it can be challenging to maintain
stable concentrations within target range in some individuals. Many factors can inﬂuence everolimus exposure
for a given dose, including hepatic function, activity of the drug efﬂux pump P-glycoprotein, the rate of everoli-
mus metabolism, drug–drug interactions (predominantly with CYP3A4 and P-glycoprotein inhibitors, including
cyclosporine), intake of fatty food, and patient adherence to the prescribed regimen. Trough concentration levels
should be monitored 4–5 days after the ﬁrst dose and after any change in everolimus dose, with additional
monitoring in response to any change in concomitant medication or other clinical circumstances which could
alter everolimus exposure. Although LC–MS/MS is the gold standard for everolimus monitoring, various immu-
noassays are widely used due to their relative simplicity and lower cost, and results can show considerable
discrepancies with reference methods due to issues such as interassay variability and cross-reactivity. Method
standardizationwill be important in the future to improve the consistency and reproducibility of results between
centers. In conclusion, based on an extensive programof clinical trials, the optimal exposure range for everolimus
in combinationwith reduced-exposure CNI therapy has been established and can be achieved inmost transplant
recipients through careful, planned TDM.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Achieving and maintaining optimal immunosuppression after solid
organ transplantation represents a complex challenge. The allograft is
highly sensitive to underimmunosuppression,which can lead to rejection,
while overimmunosuppression can lead to serious and potentially life-
threatening complications such as infection and malignancy [1,2]. Trans-
plant recipients frequently have multiple pre-existing or post-transplant
comorbidities, such as diabetes [3] and cardiovascular conditions [4],⁎ Corresponding author at: Dept of Hospital Pharmacy, RoomNa-210, ErasmusMedical
Center Rotterdam, Wytemaweg 80, 3015 CN, Rotterdam, Netherlands. Tel.: +31 10
7033202; fax: +31 10 7032400.
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transplantation, Transplant Rev (2017), http://dx.doi.org/10.1016/j.trre.20which require numerousmedications and further complicate their immu-
nosuppressive drug management.
The mammalian target of rapamycin (mTOR) inhibitor everolimus is
approved for the prophylaxis of organ rejection in adult kidney and heart
transplant recipients at low to moderate immunological risk [5]. The
approval is for everolimus to be administered in combination with
low-dose cyclosporine (CsA) and steroids. In practice it is also prescribed
with tacrolimus, the more commonly used calcineurin inhibitor (CNI)
worldwide. In liver transplantation, everolimus is indicated with low-
dose tacrolimus and steroids in recipients at all levels of immunological
risk. Similar to CNIs [6–8] and themTOR inhibitor sirolimus [9,10], evero-
limus has moderate intra-patient and inter-patient pharmacokinetic
variability [11,12], exhibits a clear drug exposure–response relationship
[13–15], and has a narrow therapeutic index [16,17]. As a result, thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Incidence of biopsy-proven acute rejection (BPAR) according to everolimus mean
trough concentration (C0) in de novo kidney transplant patients receiving everolimus
with reduced-exposure cyclosporine [14].
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tration (FDA) [19] recently categorizedeverolimusas anarrowtherapeutic
index (NTI) drug in transplantation.
Since the initial studies with everolimus, it has been apparent that
maintaining appropriate exposure of this NTI agent is essential. Pharma-
codynamic monitoring of post-transplant immunosuppressive regi-
mens, while promising [20], is not yet established and therapeutic
drug monitoring (TDM) has underpinned dosing decisions for CNIs for
several decades. More recently, it has become clear that TDM is also
essential for everolimus therapy in all transplant recipients [21–23].
Because everolimus has linear pharmacokinetics with a strong correla-
tion between trough concentration (C0) and area under the time-
concentration curve (AUC) [12], the pre-dose C0 represents a simple
and reliable index for TDM [21]. A comprehensive review of all aspects
of TDM of everolimus was recently published as a Consensus Document
by the International Association of Therapeutic Drug Monitoring and
Clinical Toxicology (IATDMCT) [21].
There is now substantial clinical evidence regarding the optimal
everolimus exposure level in organ transplant recipients and strategies
which may help to achieve this in routine practice. An important caveat
is that these data are derived primarily from renal transplantation, with
less extensive data from liver or heart transplant recipients despite speciﬁc
features in these populations (e.g. cholestasis or hypo-dysproteinemia)
which could potentially affect the pharmacokinetics of everolimus.
The current evidence base is considered here.
2. Establishing a minimum exposure threshold
The ﬁrst clinical trials of everolimus in kidney transplantation in-
volved a ﬁxed dose of everolimus with full-dose [24–26] or reduced-
dose [24] CsA. Low efﬁcacy failure rates were achieved, and everolimus
was generally well tolerated [24, 25]. Pharmacokinetic proﬁling of
everolimus was performed for up to month 6 post-transplant in two
randomized double-blind studies [24,26]. A pooled analysis of data
from these two clinical trials, published by Kovarik et al. in 2002,
showed a signiﬁcantly higher rate of biopsy-proven acute rejection
(BPAR) if everolimus C0 was below ~3 ng/mL. BPAR occurred in 32% of
these patients compared to 14–19% for C0 in the 3.5–7.7 ng/mL range,
and 9% in patients with C0 ≥ 7.8 ng/mL [13]. Results from another
ﬁxed-dose trial in kidney transplantation demonstrated a clear beneﬁt
for reduced-dose CsA versus standard-dose CsA in everolimus-treated
patients [25]. Based on these ﬁndings, the recommendations are for
everolimus dosing to be concentration-controlled using TDM, and for
CNI exposure to be reduced in everolimus-treated patients.
In subsequent years, three randomized trials of everolimus with
concomitant CsA in de novo kidney transplantation employed an evero-
limus starting dose of either 1.5 or 3.0mg/day, with TDM to ensure that
everolimus C0 did not fall below 3 ng/mL [27,28]. Exposure-response
analyses based on prospective TDM in these trials conﬁrmed that a C0
level of 3 ng/mL or higher is associated with a lower incidence of
BPAR [15,29]. More speciﬁcally, a large analysis of 779 patients by
Lorber and colleagues demonstrated that an everolimus C0 level of
≥3 ng/mL is associated with a reduced risk for early BPAR (i.e. by
month 1) and for BPAR by month 6 post-transplant (both p = 0.0001)
[15]. By month 6, patients with everolimus C0 b 3 ng/mL had a 3.4-
fold higher risk for BPAR compared to those with C0 in the range 3–8
ng/mL (p b 0.0001) [15]. Moreover, renal allograft survival was higher
when everolimus trough level was ≥3 ng/mL (96% versus 80% with
C0 b 3 ng/mL).
More recent exposure–response analyses in kidney transplant pa-
tients receiving everolimus with either concomitant CsA [14] (Fig. 1)
or tacrolimus [30] (Fig. 2) have conﬁrmed the importance of the
3 ng/mL lower cut-off for effective prevention of BPAR.
Only one trial (ASSET), in which 224 de novo kidney transplant
patients were randomized to everolimus with either low-exposure levels
or very low-exposure levels of tacrolimus, foundno signiﬁcant associationPlease cite this article as: van Gelder T, et al, Optimizing everolimus e
transplantation, Transplant Rev (2017), http://dx.doi.org/10.1016/j.trre.20between everolimus C0 and the incidence of BPAR. However, exceeding a
level of 3 ng/mL still appeared important in the very low-exposure tacro-
limus group as the mean everolimus C0 was only 2.8 ng/mL in patients
with BPAR versus 3.5 ng/mL for BPAR-free patients [31].
In de novo liver transplant patients, concentrations below 3 ng/mL
were shown to be associated with a high rate of BPAR in a randomized
dose-ﬁnding trial of 119 patients given everolimus with low-dose CsA
[32]. Three-year BPAR rates were 50%, 14% and 12%, respectively, in
patients with everolimus C0 ≤ 3 ng/mL, 3–6 ng/mL or N6 ng/mL. Lastly,
an exposure–response analysis of data from a study in which 634
heart transplant patients were randomized to everolimus at a ﬁxed
dose of 1.5 mg/day or 3.0 mg/day, or to a control arm, showed a signiﬁ-
cant relation between everolimus C0 and freedom from rejection (p =
0.02) with 3 ng/mL representing a lower threshold for efﬁcacy [33].
3. Evidence for an upper threshold for everolimus exposure
Analyses of the incidence of BPAR according to pharmacokinetic data
derived from ﬁxed-dose studies in kidney transplantation [13,29,30]
showed a mixed picture regarding an efﬁcacy advantage for high
everolimus C0 levels. An early assessment of data from two studies
in which patients were given standard-exposure CsA, found that
the incidence of BPAR at month 6 was lowest (9%) with everolimus
C0 in the 8–15 ng/mL range but that BPAR rates were not substantially
higher (14–19%) in the 3.5–7.8 ng/mL range [13]. An assessment of
237 patients given concomitant reduced-exposure CsA based on C2
monitoring (i.e. CsA concentration at two hours post-dose) in the
A2306 U.S. everolimus registration trial found no difference in BPAR
rates in the groups with everolimus C0 in the 3–8 ng/mL range versus
the N8 ng/mL group (18% in each group), and no signiﬁcant difference
in the risk for graft loss [29]. On the other hand, Lorber and colleagues,
in an analysis of 779 de novo CsA-treated kidney transplant patients
from two different randomized trials, found the rate of BPAR to be
lower with everolimus ≥8 ng/mL versus 3–8 ng/mL (8.4% versus
16.8%) but the number of events in the higher-exposure group (n =
9) was too low to draw any conclusion [15]. With concomitant tacroli-
mus (maintenance tacrolimus C0 either 3–6 or 7–10 ng/mL), Chan
et al. found no cases of BPAR when everolimus C0 exceeded 8 ng/mL,
but only four patients were in this category [30].
Two randomized clinical trials have prospectively compared out-
comes when de novo kidney transplant patients were randomized to
one of two different everolimus exposure targets, bothwith concomitant
reduced-exposure CsA [34,35]. A preplanned analysis of data from the
large A2309 trial, in which 833 patients were randomized to everolimus
targeting 3–8 or 6–12 ng/mL with reduced-exposure CsA (C0 tapered to
25–50 ng/mL after month 6), or to mycophenolate mofetil (MMF) withxposure when combined with calcineurin inhibitors in solid organ
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Fig. 2. Incidence of biopsy-proven acute rejection (BPAR) according to everolimus mean trough concentration (C0) in de novo kidney transplant patients receiving everolimus with
reduced-exposure tacrolimus [30].
Fig. 3. Incidence of selected adverse events according to everolimus mean trough
concentration (C0) at month 12 after kidney transplantation in 556 de novo kidney
transplant patients receiving everolimus with reduced-exposure cyclosporine [14].
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little difference in BPAR rates when everolimus C0 was above 8 ng/mL
(9.1–14.3%) versus 3–8 ng/mL (range 14.2–15.3%) (Fig. 1) [14]. The
second study (EVEREST) randomized newly transplanted kidney pa-
tients to everolimus with a target C0 of 3–8 ng/mL plus low-exposure
CsA, or to everolimus targeting 8–12 ng/mL with very low-exposure
CsA [35]. BPAR rates were similar between groups (14.7% and 14.1%),
but it is difﬁcult to draw conclusions since the CsA exposure in the two
groupswas also different. For kidney transplantation, the general conclu-
sion is that everolimus concentrations above 8 ng/mL do not provide an
additional beneﬁt with regard to efﬁcacy.
In addition, the available data in liver transplant patients receiving
concomitant CsA has not indicated a beneﬁt for high everolimus C0
levels (BPAR 14% versus 12% for C0 3–6 ng/mL versus N6 ng/mL) [32].
Conversely, everolimus C0 N 8 ng/mL can incur a higher rate of drug-
related adverse events, with various reports of higher statin use [30],
dyslipidemia [15,29], thrombocytopenia [29], proteinuria [36] and dis-
continuation due to adverse events [35]. In the A2309 trial, where the
two everolimus groups targeted either 3–8 or 6–12 ng/mL, the mean
everolimus C0 after month 3 was approximately 5–6 ng/mL in the
lower-exposure group and approximately 8 ng/mL in the higher expo-
sure group, and there was little difference in the adverse event proﬁles
of the two cohorts [34]. A more detailed analysis of the association
between everolimus drug exposure and safety in this study, performed
by Shihab et al., evaluated the incidence of key adverse events according
to mean everolimus exposure categories of b3, 3–6, 6–8, 8–12 and
N12 ng/mL [14]. This analysis demonstrated that the lowest rates
of wound healing events, peripheral edema and dyslipidemia with
everolimus occurred in the range 3–8 ng/mL [14] (Fig. 3). On initial
inspection, the ‘U-shaped’ curve for the incidence of wound healing
events, hypercholesterolemia and hypertriglyceridemia (Fig. 3), would
argue against a dose-dependent effect. For the lipid parameters, however,
closer examination of the data showed that the high incidences in pa-
tients with everolimus b3 ng/mL were accounted for by patients who
had high CsA exposure, and given the known hyperlipidemic effect of
CNI therapy this seems more likely to explain the frequency of lipid ab-
normalities [14]. For wound healing events, similarly, the frequency of
events at low everolimus levels (b3 ng/mL) was again due to high rates
in patients with low everolimus/high CsA concentrations [14]. Since
wound healing complications are not generally associated with CNIs,
one explanation might be that everolimus dose was lowered in response
to poor healing, but this is speculative. Peripheral edema at lower evero-
limus exposure levels did not vary according to CsA concentration [14],
and may indicate a relatively dose-insensitive effect of everolimus.Please cite this article as: van Gelder T, et al, Optimizing everolimus e
transplantation, Transplant Rev (2017), http://dx.doi.org/10.1016/j.trre.20Despite these caveats, evidence for a dose-dependent effect on event
rates above 8 ng/mL appears reliable. Of note, where everolimus is used
at substantially higher exposure levels for the treatment of solid tumors
such as renal cell cancer, meta-analyses have demonstrated substantial
increases in the risk for infections overall and for high-grade infections
[37,38], as well as for severe anemia [39,40] and other hematological
complications including thrombocytopenia [40].
4. Clinical outcomes using the recommended everolimus
target range
Based on early exposure–response analyses, and conﬁrmed by later
studies, the recommended range for everolimus C0 in kidney, liver or
heart transplant patients is 3–8 ng/mL [5]. This range assumes that
patients are receiving concomitant reduced-exposure CNI therapy,
as speciﬁed in the package insert patient information [5], and applies
to everolimus concentrations measured in whole blood by liquid
chromatography–tandem mass spectrometry (LC–MS/MS).
Randomized clinical trials in kidney [31,34,35], liver [41] and heart
[42] transplant recipients have reported rates of BPAR and other out-
comes using everolimus targeting a C0 in the range 3–8 ng/mL with
concomitant low-exposure CsA [34,35] or tacrolimus [30,31,41]. The in-
cidence of BPAR using these regimens has consistently been comparable
to a standard regimen of mycophenolic acid (MPA) with standard-
exposure CNI (Fig. 4).xposure when combined with calcineurin inhibitors in solid organ
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Fig. 4. Incidence of biopsy-proven rejection (BPAR) at month 12 post-transplant in
transplant recipients randomized in comparative studies to everolimus (EVR) targeting
C0 3–8 ng/mL with reduced-exposure calcineurin inhibitor (CNI) therapy or to
mycophenolic acid (MPA) with standard-exposure CNI in the A2309 [34], ASSET [31],
H2304 [41] and A2310 [42] trials. * Treated acute rejection. Tx, transplantation.
Table 1
Clinical factors inﬂuencing everolimus trough concentration (C0).





CsA dose increase ⇧⇧
CsA dose decrease ⇩⇩
Switch from CsA to tacrolimus ⇩⇩⇩
Switch to dispersible tablet form ⇩
Non-adherence ⇩⇩⇩
High-dose steroid therapy ⇩?
Immunoassay cross-reactivity ⇧
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everolimus concentrations are lacking. However, a clear association has
been demonstrated between higher intra-patient variability with tacro-
limus [43,44] or CsA [7] levels and an increased risk for rejection and
graft failure. Similarly, a prospective assessment of 51 sirolimus-treated
renal transplant patients with chronic allograft nephropathy showed
that those with a higher coefﬁcient of variability for sirolimus C0
(N22.9% versus b22.9%) experienced a signiﬁcantly greater risk for pro-
gressive loss of graft function (p b 0.05) [9]. There is no reason to assume
that such an effect does not also apply to everolimus-treated patients.
5. Achieving target everolimus concentrations in clinical practice
Everolimus exhibits moderate pharmacokinetic variability both
intra- and inter-patient, and it can be challenging to maintain stable
concentrations within target range in some individuals. One study in
706 kidney transplant CsA-treated patients receiving everolimus at an
initial dose of 1.5 or 3.0 mg/day observed an inter-patient variability
of 55% for everolimus C0 during the ﬁrst six months after kidney trans-
plantation,with anAUC variability of 31% [11]. The same study reported
the intra-patient variability to be 45% for everolimus C0 and 27% for AUC
[11], while an analysis of 54 maintenance kidney transplant patients
found the intra-patient variability for everolimus AUC to be in the
range 10–19% [12]. For comparison, values for intra-patient variability
in C0 and AUC, respectively, have been reported to be 36% and 32% for
tacrolimus [6], and 40–47% and 37–40% for CsA [7,8], in stable kidney
transplant patients. Thus, the observed variability for everolimus C0
and AUC may be slightly less than for CNI therapies, but nevertheless
remains substantial.
Gender, age and bodyweight do not inﬂuence steady-state exposure
of everolimus [12]. Evidence for lower everolimus exposure for the
same dose in African Americans versus other race groups is mixed
[45,46]. CYP3A5 andABCB1polymorphismsdonot seem to affect evero-
limus pharmacokinetics to any relevant extent [47]. Other factors, how-
ever, exert well-documented effects, particularly hepatic function [48],
activity of the drug efﬂux pump P-glycoprotein, the rate of everolimus
metabolismby cytochrome CYP3A4, 3A5 and 2C8 [49], drug–drug inter-
actions (predominantly via CYP3A), intake of fatty food [50], and
of course adherence to the prescribed regimen. Perhaps the most
important consideration is the concomitant CNI used, whether CsA or
tacrolimus. Everolimus, CsA and tacrolimus are metabolized by the
cytochrome P450 CYP3A4 and are all substrates for the drug transporter
P-glycoprotein [49,51]. However, in vitro studies have shown that
although both CsA and tacrolimus block efﬂux of everolimus from intes-
tinal cells via P-glycoprotein mediated channels to a similar degree, thePlease cite this article as: van Gelder T, et al, Optimizing everolimus e
transplantation, Transplant Rev (2017), http://dx.doi.org/10.1016/j.trre.20effect of CsA on other aspects of everolimus metabolism are more
complex than for tacrolimus [52]. CsA, but not tacrolimus, speciﬁcally
increased permeability — an effect possibly due to inhibition of other
transporters or metabolizing enzymes [52]. Additionally, hepatic
CYP3A4 may be inhibited to a greater extent by CsA than tacrolimus
[19], an effect which would reduce CYP3A4-mediated everolimus
clearance. Clinically, everolimus drug exposure is increased by between
two- and three-fold in the presence of CsA [53,54].With tacrolimus, this
effect is largely absent [55] such that, compared to patients given con-
current CsA, higher doses of everolimus are required in tacrolimus-
treated patients to achieve the same level of everolimus exposure.
While causes of wide variability can be identiﬁed in some cases –
most notably non-adherence, but potentially also clinical reasons such
as changes in concomitant therapies – there is often no explanation for
this phenomenon [56]. A TDM simulation of data from two large ran-
domized trials of everolimus with concomitant CsA in kidney transplant
patients predicted that amean of only two everolimus dose adjustments,
early after attainment of steady-state levels, would achieve everolimus
C0 N 3 ng/mL in 84% of patients during the ﬁrst six months post-
transplant [15]. However, in practice, and when an upper threshold is
targeted in addition to a minimum threshold in order to keep C0 within
a 3–8 ng/mL range, this may not be feasible. For patients with higher
intra-patient variability it may be wise to target everolimus trough
concentrations at or above the middle of the therapeutic range, since
episodes of under-exposure should be avoided as much as possible.
6. Practical aspects of therapeutic drug monitoring for everolimus
Routine TDMmonitoring for everolimus, based on chromatographic
measurement in whole blood, is essential. Trough concentrations
should be monitored 4–5 days after the ﬁrst dose, and after any change
in everolimus dose. The 4–5 days window allows everolimus exposure
to reach steady state [12] before making any dose change. As a mini-
mum, everolimus C0 concentrations should be measured frequently
early after transplantation and with longer intervals thereafter as long
as everolimus C0 concentrations remain stable, unless there are triggers
such as the ones discussed in the next section.
6.1. Scenarios requiring additional monitoring
Particularly close monitoring is required in certain situations
(Table 1). Patientswith hepatic dysfunction require particularlywatchful
dose titration, since almost all elimination of everolimus is via the liver:
biliary extraction accounts for 98% of elimination compared to only 2%
of urinary excretion [49]. The product license advises that the everolimus
dose should be reduced to approximately two-thirds of the normal dose
in patients with mild hepatic impairment (Child-Pugh Class A) and by
approximately half in patients with moderate or severe hepatic impair-
ment (Child-Pugh B or C) [5], and to be subsequently adjusted as neces-
sary according to TDM. Hepatic dysfunction is also likely to result inxposure when combined with calcineurin inhibitors in solid organ
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sured concentrations may not yet reﬂect steady state.
Any change in concurrent therapy with drugs which are strong
inducers or inhibitors of CYP3A4 or ABCB1 necessitates additional
monitoring of everolimus exposure [5]. One large analysis in kidney
transplant patients has demonstrated the effect of potent CYP3A4 in-
hibitors: erythromycin or azithromycin therapy reduced everolimus
clearance by approximately 20%, with itraconazole reducing clearance
by as much as three-quarters, resulting in increases in everolimus
blood concentration [46]. A subsequent study demonstrated an even
stronger interaction between everolimus and erythromycin, with
multiple-dose erythromycin increasing single-dose everolimus blood
levels by an average of 4.4-fold [57]. Other CYP3A4 and P-glycoprotein
inhibitors such as verapamil [58] and ketoconazole [59] are also associated
with well-documented increases in everolimus exposure. The CYP3A4
inducer rifampycin increased everolimus clearance by 172% and re-
duced AUC by an average of 58% [60]. Accordingly, where treatment
with CYP3A and P-glycoprotein inhibitors or inducers is introduced, or
their doses are changed, additional monitoring is necessary to adjust
the everolimus dose as necessary, guided by TDM results. As discussed
above, CsA – which like everolimus is metabolized by CYP3A4 and is
a substrate for P-glycoprotein – inhibits everolimus metabolism by
approximately 50%, so the everolimus maintenance doses should be
1.5 to 2-fold lower than in tacrolimus-treated patients [53,54,61], and
frequentmonitoring is required if the CsA dose changes or if the patient
is switched to tacrolimus. A possible effect of steroid therapy is less
clear-cut, since steroids are substrates, inhibitors and inducers of
CYP3A enzymes, and the overall impact may be dose-dependent. Corti-
costeroids appear to induce the metabolism of tacrolimus [62], and
given the similar enzymes involved in the metabolism of everolimus it
seems likely that everolimus levels may decrease if high-dose steroids
are given. Steroid-tapering steps, similarly, should prompt measure-
ment of everolimus concentrations [61].
6.1.1. Everolimus formulation
Only one formulation of everolimus, Certican® (Zortress® in the
USA), is licensed for use in transplantation, but for patients who have
difﬁculty taking standard tablets a dispersible form of Certican® is
available. If patients switch between whole tablets and the dispersible
formulation, the everolimus concentration may decrease slightly [63]
and exposure should be monitored.
Generic versions of NTI drugs such as everolimus are subject to
stricter regulatory criteria than other drugs, and any generic prepara-
tions of everolimus might need to meet stringent bioequivalence
criteria. Nevertheless, if in due course generic formulations were to
become available, switching between formulations should be avoided,
or if performed must be carefully monitored [64].
6.1.2. Logistic considerations for TDM
Even though pharmacokinetic variability is somewhat lower for
everolimus compared to CNIs, the analytical turnaround time for TDM
should ideally be the same as for CNI therapy [21]. Prompt analysis
minimizes the risk of underexposure in the ﬁrst days and weeks post-
transplant, and of overexposure to everolimus when the clinical situa-
tion changes e.g. if the CsA dose is lowered.
Samples can be transported safely in EDTA-anticoagulated tubes to
the laboratory unless temperatures and transportation time exceed
one week at up to 30 °C or three days at up to 37 °C [21]. If prolonged
storage is required, samples can be frozen at−20 °C or below.
6.1.3. Everolimus assays
As reviewed recently [21], different laboratories currently employ
different types of assays to measure everolimus concentrations, and
the methods have not been standardized. A fully validated LC–MS/MS
is the recommended method for measurement of everolimus blood
concentration, offering low limits of quantiﬁcation (≤1 ng/mL) and,Please cite this article as: van Gelder T, et al, Optimizing everolimus e
transplantation, Transplant Rev (2017), http://dx.doi.org/10.1016/j.trre.20importantly, high analytical speciﬁcity for everolimus [21]. Even within
the LC–MS/MS method, however, standardization is still required be-
tween the different laboratory-developed assays which are available.
Some laboratories use everolimus immunoassays instead of chro-
matographic techniques. In general, immunoassays require less specialist
knowledge than LC–MS/MS methods, and can be run on consolidated
clinical chemistry analyzers i.e. instruments upon which a broad spec-
trum of different laboratory parameters can be measured in parallel.
Two commercial immunoassays are available. The ﬁrst is the Quantitative
Microsphere System (QMS® Everolimus assay, Thermo Fisher Scientiﬁc/
Microgenics), which is approved to monitor everolimus concentrations
in samples fromkidney and liver transplant recipients, and can be applied
to differentmodels of general chemistry analyzers. This has the advantage
that laboratories can run the assay on almost any existing instrument,
regardless of the manufacturer, but the downside is that this limits the
reproducibility of results between the different analytical sites. The
second immunoassay is an everolimus assay recently launched by
Roche Diagnostics (Elecsys® electrochemiluminescence-immunoassay),
which completes their assay menu for immunosuppressive drugs.
Although the Elecsys® assay can only be used by laboratories that already
have the relevant Roche equipment, since it is not compatible with other
instruments, it provides a more advanced form of assay standardization.
Both immunoassays show cross-reactivity to everolimus metabolites,
but the extent of cross-reactivity to single metabolites varies between
assays [65,66]. Moreover, the two assays rely on different calibration
strategies. Calibration of the Roche assay is gravimetric, similar to LC–
MS/MSmethods, whichmakes control of accuracy easier for the labora-
tories, but due to the cross-reactivity with metabolites it overestimates
everolimus concentrations. In contrast, the QMS® assay factors up the
concentrations of calibrators artiﬁcially to compensate for cross-
reactivity with metabolites and to make readings more similar to LC–
MS/MS methods. Although this approach is more convenient at ﬁrst
glance, it bears the risk of misinterpretation. It is only valid for popula-
tion averages and can produce wide deviations from reference LC–MS/
MS concentrations for individual patients, as recognized by the manu-
facturer [65].
In particular, everolimus quantiﬁcation in samples from patients with
an aberrant drug metabolism or an unusual pattern of metabolites may
be affected [21]. A recent analysis in kidney, liver and heart transplant
patients conﬁrmed that everolimus concentrations are not consistent
between the three methods: the Elecsys® assay overestimated the con-
centration compared to LS-MS/MSwhile QMS® showed a small but sig-
niﬁcant negative deviation [67]. As a consequence of these two different
calibration strategies, higher therapeutic ranges should be applied to
Roche immunoassay results compared to those fromQMS®or LC–MS/MS.
Finally, it should be borne in mind that both immunoassays are
affected by cross-reactivity to structurally-related substances e.g. to
sirolimus. Therefore, no accurate TDMof everolimus is possiblewith either
immunoassayduring theﬁrstweek after switching from sirolimus therapy
to everolimus when both drugs are present in the blood sample.
As a consequence of these analytical issues, laboratory measure-
ments of everolimus concentrations using different techniques lack
consistency and their results cannot be considered interchangeable.
This is true even with ongoing participation in an external proﬁciency
testing program, although it is still strongly recommended regardless
of the assay type that laboratories use to continuously cross-validate re-
sults with a reference method, check the analytical quality, and control
for calibration bias [21].
In the future, method standardization may help to improve the
consistency of results between laboratories.
7. Conclusion
Since it was ﬁrst developed in the 1990s, everolimus-based immu-
nosuppression in transplant recipients has been researched in a large
number of well-designed trials. The efﬁcacy beneﬁt for maintainingxposure when combined with calcineurin inhibitors in solid organ
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tant reduced-exposure CNI therapy is well-documented. The upper
limit of 8 ng/mL in the product license avoids an increased risk for
dose-dependent mTOR inhibitor-related adverse effects without loss of
efﬁcacy compared to lower exposure levels. The bulk of data are based
on studies in kidney transplantation, but although data from liver and
heart transplant patients are more limited there is no indication of a
marked difference in the optimal target range between organ types.
A planned schedule of regular TDM assessments, with additional
measurements in response to various established inﬂuences on everoli-
mus exposure is a mandatory part of themanagement protocol. Stability
of exposure can be helped by ensuring that patients take everolimus as
indicated, i.e. consistently either with or without food and at the same
time as the CNI therapy. Where everolimus C0 varies widely despite
a steady dose, without obvious explanations for excessive variation,
adherence to the prescribed regimen should be investigated. Decision-
making regarding themethodof everolimus TDMwill frequently depend
on the available expertise and ﬁnancial constraints, but regardless of the
type of assay it is a priority to establish a rapid turnaround of sample
results and to maintain regular validation of measurements versus a
reference laboratory.
A long program of research into everolimus has reﬁned our under-
standing of how to optimize its use. Although practical challenges re-
main in achieving adequate therapeutic exposure in every patient, the
imperative is clear and vigilant monitoring via an appropriate assay
technique is a priority.
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